CN Patent

CN110117254B — 卡博替尼的制备方法

Assigned to Nanjing Junruo Biomedical Research Institute Co ltd · Expires 2022-05-13 · 4y expired

What this patent protects

本发明的目的在于提供一种更加高效的合成卡博替尼的方法，该方法以6‑硝基藜芦醛为起始物，一锅法完成还原、环合、水解反应得到6,7‑二甲氧基‑2‑羧基‑喹啉，然后经氯化亚砜处理得到为6,7‑二甲氧基‑2‑羧基‑4‑氯‑喹啉，最后在铜催化体系条件下再次一锅法完成缩合和脱羧反应得到目标产物卡博替尼。

USPTO Abstract

本发明的目的在于提供一种更加高效的合成卡博替尼的方法，该方法以6‑硝基藜芦醛为起始物，一锅法完成还原、环合、水解反应得到6,7‑二甲氧基‑2‑羧基‑喹啉，然后经氯化亚砜处理得到为6,7‑二甲氧基‑2‑羧基‑4‑氯‑喹啉，最后在铜催化体系条件下再次一锅法完成缩合和脱羧反应得到目标产物卡博替尼。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN110117254B
Jurisdiction: CN
Classification: —
Expires: 2022-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Junruo Biomedical Research Institute Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.